Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
Tirzepatide is associated with an increased risk of GIAEs, particularly among patients with T2DM, males, older adults, and those using concomitant medications. FAERS-based real-world evidence complements clinical trial data and highlights the need for individualized patient monitoring and management strategies.
Authors
- Kyung-In Joung (ORCID: https://orcid.org/0000-0002-2974-9248)
- Meng‐Si Peng (ORCID: https://orcid.org/0000-0001-6229-767X)
- Sun Jo Kim (ORCID: https://orcid.org/0000-0003-4144-7645)
- Kwang Joon Kim
- Peng Shen
Institutions
- Chonnam National University (KR)
- Wenzhou Medical University (CN)
- CHA University (KR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1371/journal.pone.0344289
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00